Adaptive Biotechnologies Corp (ADPT)

NASDAQ
7.37
-0.27(-3.53%)
After Hours
7.37
0.00(0.00%)
- Real-time Data
  • Volume:
    726,628
  • Day's Range:
    7.32 - 7.68
  • 52 wk Range:
    5.95 - 13.21

ADPT Overview

Prev. Close
7.64
Day's Range
7.32-7.68
Revenue
184.34M
Open
7.62
52 wk Range
5.95-13.21
EPS
-1.37
Volume
726,628
Market Cap
1.06B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
892,989
P/E Ratio
-5.04
Beta
1.17
1-Year Change
-5.27%
Shares Outstanding
144,311,000
Next Earnings Date
Aug 15, 2023
What is your sentiment on Adaptive Biotechnologies?
or
Market is currently closed. Voting is open during market hours.

Adaptive Biotechnologies Corp Company Profile

Adaptive Biotechnologies Corp Company Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Read More

Analyst Price Target

Average12.29 (+66.70% Upside)
High15.00
Low7.00
Price7.37
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • how can this valuation (5bn vs. 100m revenues) be justified?
    0
    • with the help of GlaxoSmithKline buy
      0
      • they will be the ones who will find a vaccine.buy
        0
        • is this just from the virus or is this a buy?
          0
          • Hoy interpretais que es buen momento para comprar? .  Después de vela bajista envolvente hay vela alcosta. Entendeís que puede tener tendencia alcista hasta 43,75$. Escribe tus pensamientos respecto al Adaptive Biotechnologies Corp
            0
            • Going to drop like a rock this week! Already 340 million in debt in just the first quarter of this year alone.
              1
              • sweet
                1